Repros Therapeutics (RPRX) Tops Q3 EPS by 2c

Repros Therapeutics (NASDAQ: RPRX) reported Q3 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29).

For earnings history and earnings-related data on Repros Therapeutics (RPRX) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
• Jefferies Downgrades Belimo Holding AG (BEAN:SW) (BLHWF) to Hold